Results 61 to 70 of about 4,565 (192)
Pharmaceuticals, 2022 The purpose of the current study was to develop Brigatinib (BGT)-loaded nanospanlastics (BGT-loaded NSPs) (S1-S13) containing Span 60 with different edge activators (Tween 80 and Pluronic F127) and optimized based on the vesicle size, zeta potential (ZP),
Randa Mohammed Zaki +5 more
doaj +1 more source
New generation anaplastic lymphoma kinase inhibitors [PDF]
, 2019 Anaplastic lymphoma kinase (ALK) gene translocations are pro-tumoral driver alterations that encompass 3*7% of non-squamous non-small cell lung cancer (NSCLC) with specific, clinic and histologic features.
Bronte G. +7 more
core +1 more source
Cancer Science, Volume 117, Issue 1, Page 272-274, January 2026.WJOG15221M is Japan's first fully remote, investigator‐initiated oncology trial, successfully enrolling 28 patients—36% remotely—by integrating trial access into the national CGP program and leveraging existing healthcare infrastructure without new digital tools.
Hiroya Taniguchi +7 more
wiley +1 more source
Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. [PDF]
, 2019 Advanced non-small cell lung cancer (NSCLC) is a complex disease comprising molecularly distinct tumor types, each with a unique biology that is becoming increasingly better characterized.
Abdel Karim, Nagla, Kelly, Karen
core
Tyrosine Kinase Inhibitors Target B Lymphocytes [PDF]
, 2023 Autoimmune disorders and some types of blood cancer originate when B lymphocytes malfunction. In particular, when B cells produce antibodies recognizing the body’s proteins, it leads to various autoimmune disorders.
Esnardo Upfold, Nikki Lyn +3 more
core +1 more source
AGING MEDICINE, Volume 8, Issue 6, Page 585-591, December 2025.Targeted therapy is associated with significantly improved prognosis and longer OS in elderly lung cancer brain metastases patients. And neurosurgical resection, radiotherapy, immunotherapy, and chemotherapy do not significantly affect OS in this patient group.
Anqi Li +14 more
wiley +1 more source
Current approaches to therapy of ALK-positive non-small cell lung cancer
Медицинский совет, 2021 This article analyzes approaches of the treatment of ALK-positive non-small cell lung cancer (NSCLC). Despite the relatively small percentage of patients with ALK-gene rearrangements, identification of this mutation is very important.
К. К. Laktionov +2 more
doaj +1 more source
Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p) [PDF]
, 2019 Background: CNS is a common site of metastases in patients with ALK-positive NSCLC. CNS metastases are associated with a number of deleterious effects, such as reduction in quality of life. However, the relationship between brain metastases and prognosis
Angelats L +19 more
core +1 more source
Синтез функціоналізованих 4,5-дигідроізоксазолів, які містять диметилфосфіноїльну групу [PDF]
, 2023 Aim. To synthesize a hybrid molecular platform incorporating dimethylphosphinoyl and 4,5-dihydroisoxazole moieties suitable for the creation of focused combinatorial libraries of compounds.Results and discussion.
Chalyk, Bohdan A., Fedyk, Andrii V.
core +2 more sources
MedComm, Volume 6, Issue 12, December 2025.Lung cancer represents a significant global health threat. Despite progress in treatment, metastasis continues to present a major clinical challenge. This article reviews the metastases of lung cancer to the liver, bone, and brain, focusing on clinical symptoms, molecular mechanisms, and treatment strategies.
Yunkui Zhang +4 more
wiley +1 more source